Andersen Partners assisted DanCann Pharma in this transaction.
DanCann Pharma was provided approximately DKK 30 million (before issue costs) in the oversubscribed IPO of units which resulted in more than 1 600 new shareholders.
The total number of shares in DanCann Pharma is 20 730 800 shares and the share capital amount to DKK 777 405. In addition, there are a total of 2 668 000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one new share in DanCann Pharma at a subscription price of DKK 6 per share during the exercise period September 1, 2021 until September 17, 2021.
DanCann Pharma A/S’ public offer was oversubscribed, and the first day of trading in DanCann Pharma A/S shares and warrants on Spotlight Stock Market is today, 12 November 2020.
DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
The Andersen Partners team included Michael Kristensen, Peter Stanstrup and Hans-Christian Ohr.
Law Firms: Andersen Partners;
Clients: DanCann Pharma A/S;